What is the official website of Novartis España ?

The official website of Novartis España is https://www.novartis.es/.

What is Novartis España's cybersecurity risk score?

Novartis España has an AI-generated cybersecurity risk score of 756 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis España experienced?

According to Rankiteo, Novartis España currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis España been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis España has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis España have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis España is not certified under SOC 2 Type 1.

Does Novartis España have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis España does not hold a SOC 2 Type 2 certification.

Does Novartis España comply with GDPR ?

According to Rankiteo, Novartis España is not listed as GDPR compliant.

Does Novartis España have PCI DSS certification ?

According to Rankiteo, Novartis España does not currently maintain PCI DSS compliance.

Does Novartis España comply with HIPAA ?

According to Rankiteo, Novartis España is not compliant with HIPAA regulations.

Does Novartis España have ISO 27001 certification ?

According to Rankiteo,Novartis España is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis España operate in ?

Novartis España operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis España have ?

Novartis España employs approximately 338 people worldwide.

Does Novartis España own any subsidiaries ?

Novartis España presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis España have ?

Novartis España's official LinkedIn profile has approximately 75,902 followers.

What is the NAICS classification code for Novartis España ?

Novartis España is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis España have a Crunchbase profile ?

No, Novartis España does not have a profile on Crunchbase.

Does Novartis España have a LinkedIn profile ?

Yes, Novartis España maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-espa-a.

How many cybersecurity incidents has Novartis España experienced ?

As of October 17, 2026, Rankiteo reports that Novartis España has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis España have ?

Novartis España has an estimated 5,773 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis España faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis España

Boost Score +25 with badge (5 left)

756

/1000

Fair

781

/1000

Fair

Novartis España Vendor Cyber Rating & Cyber Score

novartis.es

Add Your Compliance Badge

Novartis está reimaginando la medicina con el fin de mejorar y prolongar la vida de las personas. Como compañía líder mundial en desarrollo de medicamentos, utilizamos la innovación basada en la ciencia y las tecnologías digitales para crear tratamientos transformadores en áreas con necesidades médicas importantes. En nuestra misión por descubrir nuevos medicamentos, nos situamos entre las mejores compañías a nivel mundial en términos de inversión en investigación y desarrollo. Los productos de Novartis llegan a más de 800 millones de personas a nivel global y nos esforzamos en encontrar soluciones innovadoras para expandir el acceso a nuestros tratamientos. Más de 110.000 personas de 142 nacionalidades distintas trabajan en Novartis en

Novartis España

Novartis España CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis España

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis España Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis España

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis España in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis España in 2026.

Incident Types Novartis España vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis España in 2026.

Incident History - Novartis España (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis España Subsidiaries

Novartis España

Pharmaceutical Manufacturing

Website: https://www.novartis.es/

Company Size: 338

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Loading…

Novartis España Similar Companies

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, with 140 years of history, present in 140 countries worldwide, with a turnover of 4.88 billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants and is distributed across six continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Servier

servier.com

Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Loading…

NEWS

Novartis España CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

October 31, 2024 07:00 AM

Jesús Ponce, Novartis Spain CEO, at Esade Matins: “We’re committed to transformative innovation”

The CEO underlined his company's commitment to Spain where it now has 1495 employees and a 2023 year-end turnover of €1.12 billion.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-89096

SUMMARY

A flaw was found in nfs-utils. An unauthenticated remote attacker can trigger a Denial of Service (DoS) by sending repeated state notification requests to an exposed rpc.statd service. The service fails to properly release memory allocated during callback processing, leading to continuous memory growth. Sustained requests can exhaust system resources, eventually causing the service to degrade or crash.

Published

Date2026-10-16

Updated

Date2026-10-16

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2026-89088

SUMMARY

A flaw was found in parted. A heap-based buffer overflow exists in libparted's file system resizing logic when handling FAT16 volumes. By convincing a user or administrator to resize a specially crafted FAT16 file system image with malformed directory metadata, an attacker can trigger an oversized read into a fixed-size memory buffer. This issue causes memory corruption, resulting in an application crash and a denial of service (DoS).

Published

Date2026-10-16

Updated

Date2026-10-16

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

1.8

REFERENCES

CVE-2026-89085

SUMMARY

A flaw was found in parted. A heap-based buffer overflow can occur when processing a specially crafted FAT32 filesystem due to an integer calculation error during buffer allocation. A local attacker could exploit this by enticing a user or automated service to open a malicious filesystem image, resulting in an application crash leading to a Denial of Service (DoS) or potential memory corruption.

Published

Date2026-10-16

Updated

Date2026-10-16

RISK INFORMATION (Score: 6.6)

cvss3

Base Score: 6.6

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:H

Impact Score

4.7

Exploitability

1.8

REFERENCES

CVE-2026-17591

SUMMARY

A flaw was found in libarchive. An attacker can cause a Denial of Service (DoS) or potential information disclosure due to a use-after-free vulnerability, which occurs when a program reads memory that has already been released. This issue arises when the archive_entry_copy_mac_metadata() function deallocates an internal buffer before completing a data copy. An attacker who can supply input to an application utilizing this function can trigger the flaw to crash the application or read uninitialized memory data.

Published

Date2026-10-16

Updated

Date2026-10-16

RISK INFORMATION (Score: 3.6)

cvss3

Base Score: 3.6

Complexity: HIGH

CVSS:3.1/AV:L/AC:H/PR:N/UI:R/S:U/C:L/I:N/A:L

Impact Score

2.5

Exploitability

REFERENCES

CVE-2026-111802

SUMMARY

A flaw was found in Nautilus. When a removable drive or disk image is unmounted or ejected, Nautilus prompts the user to empty the trash without verifying whether the trash directory paths are symbolic links. An attacker can exploit this flaw by tricking a user into mounting a crafted storage volume and confirming the prompt to empty the trash, leading to the arbitrary deletion of files accessible to that user.

Published

Date2026-10-16

Updated

Date2026-10-16

RISK INFORMATION (Score: 6.6)

cvss3

Base Score: 6.6

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:R/S:U/C:N/I:H/A:H

Impact Score

5.2

Exploitability

1.3

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Novartis España Vendor Cyber Rating & Cyber Score

Novartis España A.I CyberSecurity Scoring

Novartis España CyberSecurity News & History

Novartis España Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis España

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis España vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis España (X = Date, Y = Severity)

Novartis España Subsidiaries

Novartis España

Novartis España Similar Companies

Lupin

UCB

Sanofi

Sandoz

MENARINI Group

Zydus Group

Alkem Laboratories Ltd.

Novo Nordisk

Servier

Novartis España CyberSecurity News

Jesús Ponce, Novartis Spain CEO, at Esade Matins: “We’re committed to transformative innovation”

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Novartis España CyberSecurity News & History

Novartis España Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis España

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis España vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis España (X = Date, Y = Severity)

Novartis España Subsidiaries

Novartis España

Novartis España Similar Companies

Lupin

UCB

Sanofi

Sandoz

MENARINI Group

Zydus Group

Alkem Laboratories Ltd.

Novo Nordisk

Servier

Novartis España CyberSecurity News

Jesús Ponce, Novartis Spain CEO, at Esade Matins: “We’re committed to transformative innovation”

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo